FOLH1 and metastatic neoplasm: In patients with high-risk or intermediate-risk disease with an unfavorable prognosis, additional imaging with prostate-specific membrane antigen (PSMA) PET/CT is offered to assess the presence of local nodal or extensive metastatic disease.